Pelvic inflammatory disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Empiric antimicrobial therapy must be administered to all patients with a confirmed diagnosis of pelvic inflammatory disease. Hospitalization may be necessary for patients who are pregnant, immunodeficient, and those with severe disease. Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes. Antimicrobial therapies generally include [[doxycycline]] and a [[β-lactam]]. [[Metronidazole]] may be added to cover anaerobic bacteria. | |||
==Medical Therapy== | ==Medical Therapy== | ||
*Empiric antimicrobial therapy must be administered to all patients with a confirmed diagnosis of pelvic inflammatory disease. | |||
*Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes. | |||
*Patients are usually treated as outpatients. Indications to hospitalize patients include the following: | |||
:*Severe symptoms (e.g. nausea, vomiting, high-grade fever) | |||
:*Pregnancy | |||
:*Immunodeficiency | |||
:*No response to PO antimicrobial therapy | |||
:*Development of complications, such as tubo-ovarian abscess | |||
:*Monitoring for unconfirmed diagnosis | |||
==Antimicrobial Therapy== | |||
==Antimicrobial | |||
*Empiric therapy | *Empiric therapy | ||
:*1. '''Parenteral Treatment''' <ref name="pmid21160459">{{cite journal| author=Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC)| title=Sexually transmitted diseases treatment guidelines, 2010. | journal=MMWR Recomm Rep | year= 2010 | volume= 59 | issue= RR-12 | pages= 1-110 | pmid=21160459 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21160459 }} </ref> | :*1. '''Parenteral Treatment''' <ref name="pmid21160459">{{cite journal| author=Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC)| title=Sexually transmitted diseases treatment guidelines, 2010. | journal=MMWR Recomm Rep | year= 2010 | volume= 59 | issue= RR-12 | pages= 1-110 | pmid=21160459 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21160459 }} </ref> | ||
| Line 159: | Line 35: | ||
*'''Specific considerations''' | *'''Specific considerations''' | ||
:*'''Tubo-ovarian abscess''' | :*'''Tubo-ovarian abscess''' | ||
::*Preferred regimen: [[ | ::*Preferred regimen: [[Doxycycline]] 100 mg PO or IV q12h for 14 days {{and}} ([[Clindamycin]] 450 mg PO qid for 14 days {{or}} [[Metronidazole]] 500 mg PO bid for 14 days) | ||
==Follow-up== | |||
*Patients should return for re-evaluation at the third day of antimicrobial therapy to evaluate for the success vs. failure of therapy. | |||
*Patients who do not improve within 3 days of therapy may require hospitalization, additional diagnostic tests, and surgical intervention. | |||
*Women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months of treatment. | |||
*Repeat testing of all women who have been diagnosed with [[chlamydia]] or [[gonorrhea]] is recommended 3–6 months after treatment, regardless of whether their sex partners were treated. All women diagnosed with acute PID should be offered HIV testing. | |||
==Treatment of Sexual Partners== | |||
*Male partners of women who have PID are often asymptomatic. | |||
*Both symptomatic and asymptomatic sexual partners of patients with pelvic inflammatory disease should be also be evaluated and treated. | |||
==References== | ==References== | ||
Revision as of 16:32, 6 October 2015
|
Pelvic inflammatory disease Microchapters |
|
Differentiating Pelvic Inflammatory Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pelvic inflammatory disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Pelvic inflammatory disease medical therapy |
|
Risk calculators and risk factors for Pelvic inflammatory disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]
Overview
Empiric antimicrobial therapy must be administered to all patients with a confirmed diagnosis of pelvic inflammatory disease. Hospitalization may be necessary for patients who are pregnant, immunodeficient, and those with severe disease. Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes. Antimicrobial therapies generally include doxycycline and a β-lactam. Metronidazole may be added to cover anaerobic bacteria.
Medical Therapy
- Empiric antimicrobial therapy must be administered to all patients with a confirmed diagnosis of pelvic inflammatory disease.
- Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes.
- Patients are usually treated as outpatients. Indications to hospitalize patients include the following:
- Severe symptoms (e.g. nausea, vomiting, high-grade fever)
- Pregnancy
- Immunodeficiency
- No response to PO antimicrobial therapy
- Development of complications, such as tubo-ovarian abscess
- Monitoring for unconfirmed diagnosis
Antimicrobial Therapy
- Empiric therapy
- 1. Parenteral Treatment [1]
- Preferred regimen (1): (Cefotetan 2 g IV q12h for 14 days OR Cefoxitin 2 g IV q6h) for 14 days AND Doxycycline 100 mg PO or IV q12h starting on day 2-3 until day 14
- Preferred regimen (2): Clindamycin 900 mg IV q8h for 14 days AND Gentamicin loading dose IV or IM (2 mg/kg of body weight) followed by a maintenance dose (1.5 mg/kg) q8h for 14 days. Single daily dosing (3-5 mg/kg) can be substituted.
- Alternative regimen (1): Ampicillin/Sulbactam 3 g IV q6h for 14 days AND Doxycycline 100 mg PO or IV q12h for 14 days
- Alternative regimen (2): Azithromycin 500 mg IV q24 for 1-2 doses followed by 250 mg PO for 5-6 days
- Alternative regimen (3): Azithromycin 500 mg IV q24 for 1-2 doses followed by 250 mg PO for 5-6 days AND Metronidazole 500 mg PO bid for 12 days
- Note: Oral doxycycline is preferred since IV doxycycline may cause pain. The bioavailabilities of both oral and IV doxycycline are similar.
- 2. IM/Oral Treatment
- Preferred regimen (1): Ceftriaxone 250 mg IM in a single dose AND Doxycycline 100 mg PO bid for 14 days ± Metronidazole 500 mg PO bid for 14 days
- Preferred regimen (2): Cefoxitin 2 g IM in a single dose AND Probenecid 1 g PO administered concurrently in a single dose AND Doxycycline 100 mg PO bid for 14 days ± Metronidazole 500 mg PO bid for 14 days
- Alternative regimen (1): Azithromycin 500 mg IV qd for 1-2 doses followed by 250 mg PO qd for 12-14 days ± Metronidazole 500 mg PO bid for 14 days
- Alternative regimen (1): Ceftriaxone 250 mg IM single dose and Azithromycin 1 g PO once a week for 14 days
- Alternative regimen (2): (Levofloxacin 500 mg PO qd for 14 days OR Ofloxacin 400 mg bid for 14 days OR Moxifloxacin 400 mg PO qd for 14 days}}) AND Metronidazole 500 mg PO bid for 14 days.
- Specific considerations
- Tubo-ovarian abscess
- Preferred regimen: Doxycycline 100 mg PO or IV q12h for 14 days AND (Clindamycin 450 mg PO qid for 14 days OR Metronidazole 500 mg PO bid for 14 days)
Follow-up
- Patients should return for re-evaluation at the third day of antimicrobial therapy to evaluate for the success vs. failure of therapy.
- Patients who do not improve within 3 days of therapy may require hospitalization, additional diagnostic tests, and surgical intervention.
- Women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months of treatment.
- Repeat testing of all women who have been diagnosed with chlamydia or gonorrhea is recommended 3–6 months after treatment, regardless of whether their sex partners were treated. All women diagnosed with acute PID should be offered HIV testing.
Treatment of Sexual Partners
- Male partners of women who have PID are often asymptomatic.
- Both symptomatic and asymptomatic sexual partners of patients with pelvic inflammatory disease should be also be evaluated and treated.
References
- ↑ Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC) (2010). "Sexually transmitted diseases treatment guidelines, 2010". MMWR Recomm Rep. 59 (RR-12): 1–110. PMID 21160459.